We evaluated whether BLP combined with SARS-CoV-2 S and influenza HA proteins could serve as an effective vaccine candidate, even in cases of co-infection with SARS-CoV-2 and influenza viruses. This evidence concerns the gene DYNLRB1 and coinfection.